(Lung Cancer) Is Tumor-Infiltrating Lymphocyte Therapy Plus Nivolumab Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
TIL Therapy Combined with Nivolumab in Anti-PD-1 Resistant NSCLC
- September 14, 2021
- Reading time: 1 minute
On August 12, 2021, Benjamin C. Creelan and colleagues at H. Lee Moffitt Cancer Center & Research Institute published in the medical journal Nature Medicine the efficacy and safety results of a Phase 1 clinical trial evaluating tumor-infiltrating lymphocyte (TIL) therapy combined with the anti-PD-1 antibody nivolumab in patients with advanced non-small cell lung cancer (NSCLC) resistant to anti-PD-1 therapy.
This single-arm Phase 1 trial enrolled patients with anti-PD-1 antibody-resistant NSCLC who had experienced disease progression after first-line nivolumab treatment. Patients received TIL therapy combined with nivolumab. The primary endpoint was safety, and the secondary endpoint was objective response rate (ORR).
Safety results (primary endpoint): The incidence of serious adverse events with TIL therapy plus nivolumab was 17% or below.
Efficacy results (secondary endpoint): Among 13 evaluable patients, 3 patients responded to treatment, tumor shrinkage was confirmed in 11 patients, and 2 achieved complete response, with a duration of 1.5 years.
Based on these Phase 1 results, Benjamin C. Creelan and colleagues concluded that TIL therapy combined with nivolumab was well tolerated in patients with anti-PD-1 resistant advanced NSCLC and may represent a promising new treatment option.
Source: https://www.nature.com/articles/s41591-021-01462-y
Tags: #Immunotherapy #ClinicalTrial
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4